Disc Medicine, Inc.
IRONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients. The company carries a $3.04B market cap, placing it firmly in the mid-cap category. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Market Cap
$3.04B
Beta
2.05
P/E (TTM)
—
P/E (Fwd)
-10.91
EPS (TTM)
$-6.58
EPS (Fwd)
$-7.26
ROE
-39.1%
ROA
-24.0%
Cash
$717.7M
Total Debt
$60.9M
Free CF
-$117.5M
52W Change
31.3%
Annual Financials
Cash vs Debt
Where IRON stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, IRON finished 11.23% above its 150-day moving average ($70.73) and 6.01% above its 200-day moving average ($74.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRON overbought or oversold?
At the September 2, 2026 close, IRON's RSI(14) was 42.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $717.7M in cash comfortably exceeding the $60.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$117.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -39.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.05 means IRON is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IRON's risk profile alongside its fundamentals and technical indicators provides a more complete picture.